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Abstract Nitric oxide generated by neuronal nitric oxide
synthase in contracting skeletal muscle fibers may regulate
vascular relaxation via a cGMP-mediated pathway. Neuronal
nitric oxide synthase content is greatly reduced in skeletal
muscles from mdx mice. cGMP formation increased in
contracting extensor digitorum longus muscles in vitro from
C57 control, but not mdx mice. The increase in cGMP content
was abolished with NG-nitro-L-arginine. Sodium nitroprusside
treatment increased cGMP levels in muscles from both C57 and
mdx mice. Skeletal muscle contractions also inhibited phenyl-
ephrine-induced phosphorylation of smooth muscle myosin
regulatory light chain. Arteriolar dilation was attenuated in
contracting muscles from mdx but not C57 mice. NO generated
in contracting skeletal muscle may contribute to vasodilation in
response to exercise.
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1. Introduction
The Ca2/calmodulin-dependent neuronal isoform of nitric
oxide synthase (nNOS) is expressed in normal skeletal muscle
where it is co-localized with dystrophin to the sarcolemma.
However, in dystrophin-de¢cient skeletal muscle from DMD
patients and mdx mice, both nNOS expression and activity are
greatly reduced [1,2]. Ca2/calmodulin-activated nNOS cata-
lyzes the conversion of L-arginine to L-citrulline and the vaso-
dilatory signaling molecule NO [3]. NO is synthesized in con-
tracting skeletal muscle [4], suggesting that increases in [Ca2]i
associated with contraction are su⁄cient to activate the Ca2/
calmodulin-dependent nNOS.
It is well established that NO derived from endothelial cells
produces vasodilation of arteries due to the subsequent acti-
vation of sGC in smooth muscle cells [5,6]. In exercising skel-
etal muscle, marked vasodilation occurs in blood vessels to
accommodate increased metabolic demands of the muscle
(functional or exercise hyperemia). Hyperemic responses in
exercising rats and humans were attenuated by NOS inhibi-
tors [7^10]. Thus, pharmacological studies in vivo and in vitro
show NO may contribute to the hyperemic response in skel-
etal muscle. However, the origin of NO, from endothelial cells
or muscle ¢bers, has not been determined. Therefore, we con-
sidered the possibility that NO produced from Ca2/calmodu-
lin-dependent nNOS in contracting skeletal muscle ¢bers dif-
fuses to adjacent vascular smooth muscle cells to elicit
localized relaxation via a cGMP-mediated pathway. NO in
vascular smooth muscle activates sGC to increase cGMP for-
mation, thereby leading to a decrease in [Ca2]i with subse-
quent inhibition of myosin RLC phosphorylation and con-
traction [5,11,12]. We found that contraction in EDL
muscles from C57 mice elicited increases in cGMP content
and reduced smooth muscle RLC phosphorylation. Rather
than rely solely on a pharmacological approach to explore
this signaling pathway, we took advantage of attenuation of
nNOS content in mdx mouse skeletal muscle. The contrac-
tion-induced increase in cGMP and arteriolar dilation was
diminished in muscles from mdx mice. These results suggest
that NO derived from nNOS in contracting skeletal muscle
contributes to the vasodilatory response to exercise. Addition-
ally, this regulatory pathway may be compromised in dystro-
phin-de¢cient skeletal muscles from mdx mice and humans
with DMD.
2. Materials and methods
C57BL and mdx mice were purchased from Jackson Laboratories.
Chemicals and biochemicals were purchased from SIGMA. Immuno-
chemical reagents were obtained from Amersham, UK. 125I-cGMP
was a gift from Dr. David Garbers.
2.1. Isolated muscles
EDL muscles (approximately 12 mm in length; 1.5 mm diameter,
and 12 mg wet weight) were isolated from fully anesthetized mice,
mounted on Grass FTO3.C force transducers and continuously gassed
with 95% O2/5% CO2 while immersed in PSS containing (in mM)
120.5 NaCl, 4.8 KCl, 1.2 MgSO4, 1.5 CaCl2, 1.2 Na2PO4, 20.4
NaHCO3, 10.0 dextrose and 1.0 pyruvate at 30‡C and pH 7.6. EDL
muscles were subjected to electrical stimulation at 30 Hz (0.2 ms
square pulse width) for 15 s, with 1 mM NG-nitro-L-arginine (NLA)
for 30 min and 10 WM sodium nitroprusside (SNP) or 10 WM phenyl-
ephrine as described below. At 1 mM NLA, the contractile properties
of the EDL muscle were not changed. Mounted muscles were
quick-frozen by tongs pre-chilled in liquid nitrogen after speci¢c treat-
ments.
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2.2. Biochemical measurements
Frozen muscles were homogenized in 10% trichloroacetic acid fol-
lowed by centrifugation. The cGMP content was measured in the
soluble fraction by a radioimmunoassay [13].
Myosin RLC phosphorylation was measured by immunoblot anal-
ysis after urea-glycerol PAGE to resolve phosphorylated and non-
phosphorylated forms of smooth muscle myosin RLC [14]. Brie£y,
protein precipitated by trichloroacetic acid was solubilized in urea
and subjected to electrophoresis in a polyacrylamide gel containing
glycerol. Resolved proteins were transferred onto PVDF membrane
and blocked with blocking reagent for 60 min. The membranes were
then probed for smooth muscle myosin RLC using a monoclonal
antibody that was speci¢c for smooth muscle myosin RLC. Bound
antibody was detected with HRP-conjugated goat anti-mouse IgG
antibody followed by development with ECL chemiluminescence de-
tection reagents. The fraction of phosphorylated RLC relative to the
total RLC was quanti¢ed by scanning laser densitometry.
2.3. Vascular response measurements in mouse cremaster muscle
Adult male mice were anesthetized with pentobarbital sodium (70
mg/kg, i.p.), tracheotomized, maintained with supplemental anesthetic
as needed via a jugular venous catheter, and kept at body temperature
of 37‡C by radiant heating. The right cremaster muscle was prepared
and the microvasculature viewed by intravital microscopy as described
elsewhere for hamsters [15] except that the vascular connections be-
tween the muscle and the epididymis were left intact. The prepared
cremaster muscles were superfused with PSS containing (in mM) 131.9
NaCl, 4.7 KCl, 2.0 CaCl2, 1.2 MgSO4, and 20 NaHCO3. The bu¡er
was equilibrated with 0^5% O2/5% CO2, balanced with N2 to give pH
7.37 at 34 þ 0.5‡C. Electrical ¢eld stimulation via silver foil electrodes
was used to contract the muscle for 2 min each at 0, 2, 4, and 8 Hz (1
ms duration, 4^10 V). Each 2 min stimulation was followed by 3 min
recovery and each was duplicated before moving to the next higher
frequency. Arteriolar diameters were measured o¡-line from video-
tapes using an electronic calliper calibrated against a videotaped stage
micrometer. The average diameter during the 10 s immediately follow-
ing stimulation was used to represent the steady-state diameter
achieved during the 2 min stimulation [16].
3. Results
3.1. cGMP formation in mouse EDL skeletal muscle
Under control, resting conditions, EDL muscles from C57
mice contained 2 fmol cGMP per mg wet wt tissue (Fig. 1A).
cGMP content was increased 246% with electrical stimulation.
Treatment of the muscles with 1 mM of the NOS inhibitor
NLA did not a¡ect the resting level of cGMP but completely
inhibited the increase due to electrical stimulation. Addition
of SNP increased cGMP content to 4 fmol cGMP per mg wet
wt tissue which was not a¡ected by 30 min pretreatment with
NLA (Fig. 1A).
cGMP formation in EDL muscles from mdx mice was also
measured (Fig. 1B). In contrast to results with muscles from
C57 mice, electrical stimulation of mdx muscles did not in-
crease cGMP formation (Fig. 1B). However, the muscles were
responsive to the NO donor SNP. Thus, contraction of mdx
muscles with attenuated nNOS expression does not lead to
increased cGMP formation. However, an NO-responsive gua-
nylyl cyclase is apparently still present.
3.2. Smooth muscle myosin regulatory light chain
phosphorylation in isolated skeletal muscle
The extent of phosphorylation of vascular smooth muscle
RLC was measured with a monoclonal antibody speci¢c for
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Fig. 1. Nitric oxide generated in contracting EDL muscle stimulates
cGMP formation. Isolated EDL muscles from C57 mice (A) or mdx
mice (B) were either electrically stimulated at 30 Hz for 15 s, incu-
bated with 1 mM NLA (30 min), or 10 WM SNP (30 s), or sub-
jected to combinations as indicated. Values are means þ S.E.M. for
at least four muscles for each group.
Fig. 2. A monoclonal antibody reacts speci¢cally with smooth
muscle RLC. Increasing amounts of puri¢ed smooth and skeletal
muscle RLC were subjected to SDS-PAGE and Western blotting. A
monoclonal antibody raised against smooth muscle RLC was used
to detect smooth muscle and skeletal muscle myosin RLCs.
Fig. 3. Skeletal muscle contraction inhibits smooth muscle RLC
phosphorylation. Non-phosphorylated (smRLC) and phosphorylated
(smRLC-P) smooth muscle myosin RLCs were resolved by urea/
glycerol PAGE and detected with a monoclonal antibody raised
against the smooth muscle RLC. Mean values þ S.E.M. of smooth
muscle RLC phosphorylation in EDL muscles treated for 60 s with
10 WM phenylephrine (Phe), electrical stimulation for 15 s, or Phe
for 60 s plus electrical stimulation during the last 30 s (nv 6).
K.S. Lau et al./FEBS Letters 431 (1998) 71^7472
smooth muscle RLC. This antibody binds to smooth muscle
RLC and shows no immunoreactivity to skeletal muscle RLC
(Fig. 2). The monoclonal antibody detected smooth muscle
RLC directly in Western blots of skeletal muscle homogenates
(Fig. 3) where the smooth muscle RLC is a much less abun-
dant protein relative to the skeletal muscle RLC. The extent
of smooth muscle RLC phosphorylation was low under rest-
ing conditions (6 0.05 mol phosphate/mol RLC) or with elec-
trical stimulation (Fig. 3). However, with the addition of the
K-adrenergic agonist, phenylephrine, the extent of smooth
muscle RLC phosphorylation increased to over 0.4 mol phos-
phate/mol RLC. More importantly, the extent of phosphoryl-
ation in the presence of phenylephrine decreased signi¢cantly
in response to electrical stimulation of the skeletal muscle.
3.3. Vascular response to skeletal muscle contraction
Contraction-induced increases in arteriolar diameters deter-
mined in ten vessels in seven mdx mice and nine vessels in nine
C57 mice showed a signi¢cantly diminished vascular dilation
in the mdx vessels (Fig. 4). From an initial similar resting
diameter (9.5 þ 2.0 Wm in mdx vs. 6.7 þ 0.8 Wm in C57), the
mean response of the mdx mice was less than that of controls
at each stimulation frequency (P6 0.01). All vessels studied
were second and third order arterioles with similar mean max-
imal diameters of 27.8 þ 2.1 Wm and 26.5 þ 3.0 Wm for control
and mdx muscles, respectively.
4. Discussion
We examined the hypothesis that NO produced by nNOS in
skeletal muscle ¢bers may contribute to vascular relaxation
during muscle contraction via the cGMP-myosin RLC cas-
cade. cGMP content increased 246% in contracting mouse
skeletal muscles in close agreement with the 230% increase
in cGMP content reported for contracting frog gastrocnemii
muscles subjected to the same stimulation protocol [17]. At
the time this latter report was published twenty years ago, NO
and NOSs were unknown so that the mechanism accounting
for the increased cGMP formation could not be explored. We
show the contraction-dependent increase in cGMP formation
was totally abolished with the NOS inhibitor NLA. However,
a similar increase in cGMP production by the NO donor SNP
was not a¡ected by the NOS inhibitor. Thus, increased cGMP
formation in contracting skeletal muscle was due to activation
of a NOS. In mdx mice, the amount of nNOS in skeletal
muscle is greatly reduced [2]. This observation may explain
why contraction of mdx muscles did not lead to increased
cGMP formation. However, the cGMP response to SNP in
mdx muscle was una¡ected, indicating the cGMP signaling
cascade is probably intact. These results support the hypoth-
esis that nNOS stimulates cGMP formation in response to
contractions in skeletal muscle.
While the mechanisms by which cGMP acts to decrease
cytosolic Ca2 concentrations are not fully de¢ned [5,12],
cGMP is recognized as an important second messenger mod-
ulating smooth muscle contractility. Increases in [Ca2]i acti-
vate Ca2/calmodulin-dependent myosin light chain kinase,
resulting in phosphorylation of smooth muscle myosin RLC
and contraction [18,19]. This cascade of cellular responses is
inhibited by increases in cGMP formation which act to de-
crease [Ca2]i. In stimulated C57 EDL muscle, smooth muscle
myosin RLC phosphorylation was inhibited, presumably due
to the cGMP-mediated decrease in smooth muscle [Ca2]i.
However, it is not known if the cGMP response to electrical
stimulation or SNP is speci¢cally localized to vascular smooth
muscle. cGMP-dependent vasodilation of arterioles has been
reported in rat cremaster muscle [20] and other tissues [21,22].
We also ¢nd that the arteriolar response to contraction in
cremaster muscles from mdx mice was attenuated, providing
physiological evidence consistent with our hypothesis.
In summary, these ¢ndings are consistent with the hypoth-
esis that Ca2-dependent nNOS is activated in contracting
skeletal muscle, and the NO produced results in increased
amounts of cGMP with subsequent inhibition of smooth
muscle myosin RLC phosphorylation. This NO-dependent
cascade provides a cellular mechanism supporting functional
hyperemia in contracting skeletal muscle. This hyperemic re-
sponse may be compromised in dystrophin-de¢cient muscles
in patients with DMD.
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